Several of the most respected fund managers in the world predicted a Trump Presidency would be good for biotech… and for biotech investors. Todd Hagopian, the most successful biotech fund manager in the market today, has already seen this market wisdom pay off.
His Marketocracy Biotech Fund is up over 30%, and he thinks there’s more to gain.
Being in the right sector at the right time is one of the most powerful ways to beat the market, and medical device makers are shaping up to be the best niche in med-tech stocks this year. Which is why we feel there couldn’t be a better time to introduce Financial Trends readers to Zenosense, Inc. (OTC: ZENO). This emerging medical device company is starting to gain investor’s attention, for very good reasons.
The cardiac diagnostic market worldwide is $7.2 billion – and growing, and ZENO has an edge. Led by renowned physician, Dr. Nasser Dejennati, ZENO is using patented technology to develop a hand-held device for quick analysis of heart attack victims that saves emergency medical professionals precious time in evaluating their patients condition, and a better opportunity to save lives.
Their groundbreaking device, called MIDS Cardiac, gives medical providers the same benefits as lengthy laboratory testing only in a hand-held device, with results available in minutes. This could be of huge value to Financials Trend readers. ZENO is about to move to main street among medical technology companies, with potential revenue for the MIDS cardiac device beginning as early as 2018. That gives Zenosense critical leverage, both in medical and financial terms.
Big Bucks and High-Flying Shares
Zenosense started trading in 2013. There are approximately 22 million shares issued and outstanding, which is trading at a market cap valuation of only $6.8 million. So, the UPSIDE is HUGE!!! How huge, you ask? Well, shares of ZENO bolted to a high of $4.00 on April 10th on stellar volume of over 17 million shares. So, what made its stock bolt like that? MIDS Quantitative Testing Results… which was coincidentally released 30 days prior to ZENO shares taking off.
While ZENO shares soared, the stock quickly retreated, reaching a low of $0.21 before slowly gaining momentum to where it trades today, slightly above $0.30. We estimate ZENO could begin selling its MIDS Cardiac device in 2018, if it only gets 1/10th of 1 percent of the Market, it would generate $7 million in sales. However, given that this would be the only handheld device which could deliver high sensitivity laboratory results within minutes, it’s quite probable that Zenosense could grow to as much as 1% of the global cardiac diagnostic and that means NORTH OF SEVENTY MILLION IN SALES.
Frankly, Financials Trend looks for a market development somewhere in the middle of that forecast over a two-to-three year period, so its shares could – given patience to a portfolio position – see or even surpass its 2017 high of $4.00 per share.
This is NOT a one-horse pony show
ZENO revealed in its March 10, 2017 news release on its testing results that the device could be extended to other applications. “We believe that, in addition to cardiac markers, the MIDS technology platform can be applied across a wide spectrum of diagnostic tests. The Company believes there is an enormous potential market.”
MIDS Cardiac™ device is being developed through a joint venture ownership in MIDS Medical Ltd, a UK organization that’s staffed and equipped to develop more applications using the MIDS technology and not require separate patents. That gives ZENO a real edge over other medical device companies as MIDS Medical Ltd can deliver where other small medical device companies can’t.
The MIDS, or Magnetic Immunoassay Detection System, is being developed for Point of Care (POC) hand held devices by the MIDS Medical Ltd team. The patented MIDS technology is expected to enable handheld, inexpensive devices to reach levels of accuracy at the POC currently available only in large, slow and expensive central laboratory analyzers, MIDS Medical Ltd. states on its website.
MIDS Cardiac™ is being developed to deliver the following key features:
- A game-changing Point of Care sensitivity and accuracy improvement, equal or superior to high sensitivity cardiac biomarker assays performed on central laboratory analyzers
- Patient friendly, tiny finger prick sample rather than treated venous blood draw
- An industry leading tiny 5 microliter blood sample, 3 to 400 times smaller (1 assay) than existing Point of Care devices for cardiac marker tests
- Test times 3 to 7 times faster (1 assay) than existing Point of Care devices
- Capable of 3 multiplexed assays (3 cardiac biomarkers in a single test strip)
- Automated operation by minimally trained personnel even in an ambulatory setting
- Considerably more cost effective for healthcare providers than existing test devices
That means these handheld devices can be used at the scene of an accident, in an ambulance, the ER or on the ward – and ZENO is right in the middle of it.
Cardiovascular disease is the leading cause of death in the western world. It claims the lives of 1 in 4 Americans. In the case of an emergency, rapid diagnosis in the first “Golden Hour” is crucial to survival. On the flip side, the ability to rule out non-emergency cardiac events for patients complaining of chest pain could save healthcare providers BILLIONS.
Do you see why we think ZENO has the potential to once again reach – or even surpass its $4.00 high?
So what is MIDS Technology?
Immunoassay tests are commonly used to diagnose a whole host of disease / medical conditions. In general, the technology behind them relies on the manipulation of magnetic nanoparticles as analyte labels, moving them through the assay process and concentrating them in a detection area. These particles have the unique property of being super-paramagnetic; they are only magnetic when placed in a very strong magnetic field (bias field), which is critical to their success as labels for analyte detection. These analytes/nanoparticles are usually captured and immobilized in a line, typically on a nitrocellulose strip or on a microfluidic strip deposition area.
Conventional assays detect and measure these analytes on their capture line or trap areas using optical instruments to measure reflectance, contrast, color change or fluorescence emitted from the nanoparticle coating. However, as the analyte in biological fluids travels through the whole thickness of the test strip a high percentage (over 70%) of these analytes are not detected by the optical measuring device, resulting in poor accuracy, especially in POC devices where optical instrument quality is limited by cost and/or size.
While other devices are limited to imperfect optical detection, MIDS also detects magnetically, to a whole new level of accuracy: Like other devices, the MIDS patented technology not only uses a cost effective, bespoke sensor to measure optically, but crucially also utilizesminiaturized highly sensitive custom built “Hall Effect” magnetic sensors embedded within a test strip as a Lab-On-Chip device. Hall Effect sensors are commonplace; to be found in virtually every electronic device from an alarm clock to a zip drive. They sense low levels of magnetic signature from magnetic device components. Immunoassay nanoparticles are paramagnetic, albeit on a much smaller scale: only in an adequately strong magnetic field will they behave magnetically.
The MIDS patented technology can separate the relatively large ambient magnetic field needed to induce the paramagnetic effect in the particles from the tiny, nano-Tesla paramagnetic signature of the particles themselves. A precisely located bespoke Hall effect sensor is then used to detect these tiny passing paramagnetic signatures.
Now, if you had troubleunderstanding all of that, what it says in simple terms is that a drop of blood placed in the handheld device is quickly read, accurately, which means the user can identify the heart condition very quickly, saving time, money and lives. Below is more on the test strip itself.
Incorporating the patented MIDS technology, MIDS Cardiac™ uses highly sensitive, custom built “Hall Effect” magnetic sensors embedded within a disposable microfluidic test strip as a “Lab-On-Chip” device. This can detect extremely low levels (nano-Tesla) of magnetic field disturbance caused by the test particles used in immunoassay tests making MIDS Cardiac™ different from anything in the market. Detection at these levels is unheard of and should allow Gold Standard Laboratory accuracy with results available in minutes- an absolute “Game Changer” and true “Blockbuster” device.
The medical device industry is heating up. Just take a look at some of these other players and you’ll see why ZENO is perfectly positioned for massive gains:
- Trinity Biotech (Nasdaq: TRIB) shot up 2,672%, from $1.05 to $28.00.
- Pulse Biosciences (Nasdaq: PLSE) soared up 760%, from $5.20 to $39.50.
- Invivo Therapeutics Holding (Nasdaq: NVIV) saw gains of 911%, from $1.96 to $17.87.
An absolute must have for medical professionals, Zenosense could rapidly penetrate an immunoassay market which is projected to be worth $23.7 billion per year worldwide by 2019. A true blockbuster in the making, ZENO has real potential to be the next high growth stock of 2017 and beyond.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of financialstrend.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: